THE STORY IN BRIEF
  • The societies include impact on work or daily tasks among the reasons to offer prevention.
  • Acute medicines and preventive medicines serve different purposes.
  • The guideline asks clinicians to weigh effectiveness, side effects, costs and patient priorities together.
MAKE TIME FOR A GOOD READ
Inside this story 1 perspectives

A person who loses a shift to migraine may have more to say at a medical appointment than the number of attacks that month. A joint guideline published on 31 August by the American Academy of Neurology and the American Headache Society asks clinicians to consider how migraine affects a person's work and daily activities when offering preventive treatment. Its advice makes a familiar piece of information, what someone had to stop doing, part of a clinical conversation.

The two organisations say clinicians should offer preventive treatment to adults who have four or more migraine days a month, four or more days of moderate to severe headache a month, or whose migraine interferes with work or daily tasks. These are alternative grounds for a conversation. Someone whose attacks regularly disrupt important activities has a reason to bring that up even if the count appears modest. The recommendation concerns people with migraine and a decision with a clinician.

Migraine can involve nausea, difficulty thinking, and sensitivity to light and sound, alongside head pain. An attack can run from hours into days. The colleague who left a brightly lit meeting and the parent who could not finish an ordinary task may each have an example worth describing. A count of days tells the clinician about frequency. Those examples explain what the days cost the person.

Two different purposes for medication

Acute treatments address symptoms during an attack. Preventive medicines are taken on a continuing schedule to reduce future attacks or their impact. The new guidance updates a document from 2012 and brings established medicines together with newer treatments that target migraine more specifically. It considers both episodic and chronic migraine. The evidence varies by treatment, and the guideline assesses how confident clinicians can be in a medicine's effectiveness.

A useful appointment can therefore turn to practical differences between options. The societies ask clinicians to discuss side effects, costs, how a medicine is taken, and how strong the evidence is. Some treatments taken by mouth require regular doses. Some injectable options are given at much longer intervals. A medicine used for another condition may also help with migraine. Which option fits depends in part on the person's other health needs and preferences, and on a clinician's assessment.

There is another question worth asking before leaving the room: when will patient and clinician review the treatment together? The updated guidance calls for assessment at the appropriate interval after a new medicine starts. The account of missed work, lost concentration or abandoned plans then has a second purpose. Alongside the number of headache days, it gives both people something concrete to revisit when deciding how well the treatment is serving its purpose.

BB
ABOUT THE AUTHOR

Beyond Business Editors

Editorial desk

Beyond Business connects global developments with the decisions, ambitions and everyday lives of its readers. Our editorial desk explores the stories shaping our world.

More from this author
Keep the perspective.